MUSA's Validated Cloud: Fully Qualified Citrix® Application…

MUSA is pleased to announce that they’ve documented and deployed a Citrix platform for GxP-hosted and FDA-compliant applications in Validated Cloud using the Citrix XenApp and Netscaler lines of…(PRWeb December 20, 2012)Read the full story at ht…


Click here for reuse options!
Copyright 2012 Biotechblog

MUSA’s Validated Cloud: Fully Qualified Citrix® Application…

MUSA is pleased to announce that they’ve documented and deployed a Citrix platform for GxP-hosted and FDA-compliant applications in Validated Cloud using the Citrix XenApp and Netscaler lines of…(PRWeb December 20, 2012)Read the full story at ht…


Click here for reuse options!
Copyright 2012 Biotechblog

Drug Patent Expirations for Dec 12 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations


ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents


Simple flat-rate database subscription
plans

Ultimate Plan Premium
Plan
Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Discount
schedule
    Contact






Drug Patent Expirations for December 12 2012

Tradename Applicant Generic Name Patent
Expiration
COMBIPATCH Novartis estradiol; norethindrone acetate Dec 12, 2012
DAYTRANA Noven Pharms Inc methylphenidate Dec 12, 2012
MUSE Meda Pharms alprostadil Dec 12, 2012
PROHANCE Bracco gadoteridol Dec 12, 2012
PROHANCE MULTIPACK Bracco gadoteridol Dec 12, 2012
VIVELLE-DOT Novartis estradiol Dec 12, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.








DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details


DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Click here for reuse options!
Copyright 2012 Biotechblog

Like this:


Continue reading

Drug Patent Expirations for Dec 13 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations


ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents


Simple flat-rate database subscription
plans

Ultimate Plan Premium
Plan
Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Discount
schedule
    Contact






Drug Patent Expirations for December 13 2012

Tradename Applicant Generic Name Patent
Expiration
ALPHAGAN P Allergan brimonidine tartrate Dec 13, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.








DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details


DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Click here for reuse options!
Copyright 2012 Biotechblog

Share this:

Like this:

Like Loading...

Continue reading

Drug Patent Expirations for Dec 17 2012

Republish
Reprint

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations


ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents


Simple flat-rate database subscription
plans

Ultimate Plan Premium
Plan
Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Discount
schedule
    Contact






Drug Patent Expirations for December 17 2012

Tradename Applicant Generic Name Patent
Expiration
SYMBICORT Astrazeneca budesonide; formoterol fumarate
dihydrate
Dec 17,
2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.








DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details


DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Click here for reuse options!
Copyright 2012 Biotechblog

Like this:


Continue reading

Alpha Source, Inc. Donates $1,000 to the Marine Toys for Tots…

Republish
Reprint

Alpha Source, Inc., a Wisconsin-based, medical equipment parts distributor and battery pack manufacturer, donates $1,000 towards toys for the Marine Toys for Tots Foundation. This local component of…(PRWeb December 20, 2012)Read the full story at …


Click here for reuse options!
Copyright 2012 Biotechblog

Like this:


Continue reading

The Honey Drop, the Ultimate Fuel for Astronauts, will be Powering…

Republish
Reprint

Island Abbey Foods Ltd.™ will be breaking the boundaries of space as its flagship product, the Honibe® Honey Drop®, gains altitude on its way to the International Space Station to become a…(PRWeb December 20, 2012)Read the full story a…


Click here for reuse options!
Copyright 2012 Biotechblog

Like this:


Continue reading

Bayer CropScience Purchases Land Adjacent to its Research Triangle…

Republish
Reprint

Acquired Parcel from Research Triangle Foundation Positions Company for Future Expansion(PRWeb December 20, 2012)Read the full story at http://www.prweb.com/releases/2012/12/prweb10258788.htm


Click here for reuse options!
Copyright 2012 Biotechblog

Like this:


Continue reading

Trudeau Institute Awarded Grant to Investigate a New Approach to…

Republish
Reprint

Northeast Biodefense Center Grant Funds Research to Increase Survival Rates from Life-Threatening Bacterial Infections(PRWeb December 20, 2012)Read the full story at http://www.prweb.com/releases/2012/12/prweb10258569.htm


Click here for reuse options!
Copyright 2012 Biotechblog

Like this:


Continue reading

Stemedica Issued U.S. Patent For Stem Cell Treatment of Diabetic…

Republish
Reprint

Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors announced that the Company has been issued U.S. Patent #8,318,485 by the United States…(PRWeb December 20, 2012)Read the full story at h…


Click here for reuse options!
Copyright 2012 Biotechblog

Like this:


Continue reading
%d bloggers like this: